Innate Pharma S.A. - American Depositary Shares (IPHA)
IPHA moved a median of 0.00% 30 minutes after news, and -0.61% by the close. How IPHA actually reacts to news — the realized, point-in-time move the market made, measured across 153 labeled events over the last three years with zero look-ahead.
IPHA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 30% | 116 |
| 30-min | 0.00% | 39% | 134 |
| 60-min | -0.56% | 35% | 142 |
| to close | -0.61% | 38% | 146 |
| Middle 50% of IPHA reactions | -1.69% to +0.90% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 153 |
Half of all Innate Pharma S.A. - American Depositary Shares news events land between -1.69% and +0.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IPHA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.71% | 50% | -0.48% |
| Rating reiterations | 36 | -0.29% | 42% | -1.18% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how IPHA ranks against every other measured name →
That’s how IPHA usually reacts — get an email when it moves on news →Email me when IPHA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IPHA's baseline. Nothing else.
Recent IPHA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K Innate Pharma SA For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -1.60% | -4.02% | |
| Form 6-K Innate Pharma SA For: Sep 16 | SEC filing · Form 6-K | SEC EDGAR | -1.60% | -4.02% | |
| Form 6-K Innate Pharma SA For: Sep 17 | SEC filing · Form 6-K | SEC EDGAR | -1.60% | -4.02% | |
| Innate Pharma Reports First Half 2026 Business Update and Financial Results | Press release | Business Wire | -1.60% | -4.02% | |
| Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions | Press release | Business Wire | -1.60% | -4.02% | |
| Sobi and Innate announce partnership is now effective following completion of closing conditions | Press release | PR Newswire | -1.60% | -4.02% | |
| Form 6-K Innate Pharma SA For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | -0.52% | -1.57% | |
| Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update | Press release | Business Wire | -0.52% | -1.57% | |
| Form 6-K Innate Pharma SA For: Sep 02 | SEC filing · Form 6-K | SEC EDGAR | — | +0.46% | |
| Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | — | +0.46% | |
| Form 6-K Innate Pharma SA For: Aug 19 | SEC filing · Form 6-K | SEC EDGAR | +0.94% | -2.34% | |
| Form 6-K Innate Pharma SA For: Aug 14 | SEC filing · Form 6-K | SEC EDGAR | -1.83% | +0.00% | |
| Innate Pharma Announces Conference Call and Webcast | Press release | Business Wire | -1.83% | +0.00% | |
| Form 6-K Innate Pharma SA For: Aug 10 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | — | |
| Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma | Press release | Business Wire | +0.42% | — | |
| Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer | Press release | Business Wire | +0.42% | — | |
| Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma | Press release | PR Newswire | +0.42% | — | |
| Form 6-K Innate Pharma SA For: Jul 23 | SEC filing · Form 6-K | SEC EDGAR | -0.56% | -0.56% | |
| Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference | Press release | Business Wire | -0.56% | -0.56% | |
| Form 6-K Innate Pharma SA For: Jul 21 | SEC filing · Form 6-K | SEC EDGAR | — | -0.28% | |
| Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) | Press release | Business Wire | — | -0.28% | |
| Form 6-K Innate Pharma SA For: May 22 | SEC filing · Form 6-K | SEC EDGAR | +1.06% | -3.17% | |
| Outcome of Innate Pharma’s 2026 Annual General Meeting | Press release | Business Wire | +1.06% | -3.17% | |
| Form 6-K Innate Pharma SA For: May 19 | SEC filing · Form 6-K | SEC EDGAR | -3.18% | -7.73% | |
| Innate Pharma to participate in the Jefferies Global Healthcare Conference | Press release | Business Wire | -3.18% | -7.73% | |
| Form 6-K Innate Pharma SA For: May 13 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -6.38% | |
| Innate Pharma Reports First Quarter 2026 Business Update and Financial Results | Press release | Business Wire | +0.00% | -6.38% | |
| Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026 | Press release | Business Wire | — | -3.55% | |
| Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update | Press release | Business Wire | +4.20% | +5.59% | |
| Innate Pharma to Participate in the D. Boral Capital Global Conference | Press release | Business Wire | +0.00% | -4.86% | |
| Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 | Press release | Business Wire | +0.59% | -1.19% | |
| Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026 | Press release | Business Wire | +0.00% | +3.60% | |
| Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026 | Press release | Business Wire | +0.00% | +3.60% | |
| Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event | Press release | Business Wire | -1.99% | -2.69% | |
| Innate Pharma to Participate in the Kempen Life Sciences Conference | Press release | Business Wire | -2.74% | -4.79% | |
| Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report | Press release | Business Wire | +0.00% | +1.48% | |
| Innate Pharma Reports Full Year 2025 Financial Results and Business Update | Press release | Business Wire | -1.54% | -3.85% | |
| Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026 | Press release | Business Wire | — | -1.74% | |
| Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference | Press release | Business Wire | +0.00% | -0.58% | |
| Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025 | Press release | Business Wire | +0.00% | +1.72% | |
| Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 | Press release | Business Wire | +2.29% | +2.87% | |
| Innate Pharma Releases Its 2026 Financial Calendar | Press release | Business Wire | +1.61% | -0.54% | |
| Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 | Press release | Business Wire | +0.00% | +1.04% | |
| Innate Pharma to Present at Jefferies Global Healthcare Conference | Press release | Business Wire | — | +1.11% | |
| Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results | Press release | Business Wire | -3.61% | — | |
| Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL | Press release | Business Wire | -1.03% | +17.95% | |
| Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates | Press release | Business Wire | +0.00% | +0.00% | |
| Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 | Press release | Business Wire | — | -5.58% | |
| Innate Pharma Reports First Half 2025 Business Update and Financial Results | Press release | Business Wire | +1.87% | -2.38% | |
| Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event | Press release | Business Wire | — | -0.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IPHA section they belong to.
Where else IPHA is measured.
IPHA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Innate Pharma S.A. - American Depositary Shares's median reaction calculated?
Every labeled IPHA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 153 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of IPHA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IPHA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.